Levels of IL-6 and TNF-α in diabetic rats: effect of quercetin

Enver Ahmet Demir, Mehmet Öz, Muhammed İkbal Alp, Hasan Serdar Gergerlioğlu
3.852 1.041

Öz


Flavonoids are widely used phenolic compounds in traditional medicine due to their health-beneficial features. Quercetin is a remarkable member of flavonols, which is a sub-family of flavonoids, with its broad biological activity. Using flavonoids as adjuvant agents in the treatment of diabetes mellitus is frequently being debated. Inflammation, which is mentioned in the
pathophysiology of diabetes, may be seen as a target for the adjuvant therapy. Thereby, in the present study, we aimed to investigate the effects of quercetin on the plasma inflammatory cytokines, namely interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in diabetic rats. Total six groups were assigned as controls and treatments (50 mg/kg and 100 mg/kg
quercetin) in diabetic and non-diabetic main groups. We found that diabetes resulted in a significant increase of plasma IL-6 and TNF-α levels (respectively p=0,01 and p=0,01). Both doses of quercetin reduced plasma IL-6 and TNF-α to the levels that in non-diabetic animals (respectively p=0,01 and p=0,01). In terms of inflammatory cytokine levels, there was no significance between non-diabetic quercetin injected and control animals (p=0,99). Therefore, we assumed that quercetin acts as an immunomodulator rather than an immunosuppressant in diabetic rats.


Anahtar kelimeler


Quercetin, diabetes mellitus, inflammation, interleukin-6, tumor necrosis factor-α

Tam metin:

PDF

Referanslar


International Diabetes Federation. IDF Diabetes Atlas, 6th

ed.th ed. 2013 [cited 2014 Feb 12]. Available from URL:

http://www.idf.org/diabetesatlas.

Bending D, Zaccone P, Cooke A. Inflammation and type one

diabetes. International Immunology. 2012;24(6); 339–346.

Kahn SE, Cooper ME, Del Prato S. Pathophysiology and

treatment of type 2 diabetes: perspectives on the past,

present, and future. The Lance. 2014;383(9922); 1068–1083.

Cade WT. Diabetes-related microvascular and

macrovascular diseases in the physical therapy setting.

Physical Therapy. 2008;88(11); 1322–1335.

Gabay C. Interleukin-6 and chronic inflammation. Arthritis

Research & Therapy. 2006;8 Suppl 2; S3.

Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6

Induces Cellular Insulin Resistance in Hepatocytes. Diabetes.

;51(12); 3391–3399.

Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces

insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and

tumor necrosis factor-alpha, overexpressed in human fat cells

from insulin-resistant subjects. The Journal of Biological

Chemistry. 2003;278(46); 45777–45784.

Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-

Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance

associated to obesity: the link TNF-alpha. Archives of

Physiology and Biochemistry. 2008;114(3); 183–194.

Kumar S, Pandey AK. Chemistry and biological activities of

flavonoids: an overview. The Scientific World Journal.

;2013; 162750.

Formica JV, Regelson W. Review of the biology of

Quercetin and related bioflavonoids. Food and Chemical

Toxicology. 1995;33(12); 1061–1080.

Kelly GS. Quercetin. Monograph. Alternative Medicine

Review. 2011;16(2); 172–194.

Kanter M. Protective effects of thymoquinone on

streptozotocin-induced diabetic nephropathy. Journal of

Molecular Histology. 2009;40(2); 107–115.

Akash, Muhammad Sajid Hamid, Rehman K, Chen S. Role

of inflammatory mechanisms in pathogenesis of type 2

diabetes mellitus. Journal of Cellular Biochemistry.

;114(3); 525–531.

King GL. The role of inflammatory cytokines in diabetes

and its complications. Journal of Periodontology. 2008;79(8

Suppl); 1527–1534.

Bottino R, Lemarchand P, Trucco M, Giannoukakis N. Gene-

and cell-based therapeutics for type I diabetes mellitus.

Gene Therapy. 2003;10(10); 875–889.

Nicholas D, Odumosu O, Langridge, William H R.

Autoantigen based vaccines for type 1 diabetes. Discovery

Medicine. 2011;11(59); 293–301.

Phillips JM, Parish NM, Raine T, Bland C, Sawyer Y, De La

Peña, Hugo ve ark. Type 1 diabetes development requires

both CD4+ and CD8+ T cells and can be reversed by nondepleting

antibodies targeting both T cell populations. The

Review of Diabetic Studies 2009;6(2); 97–103.

Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM.

Beta cell MHC class I is a late requirement for diabetes.

Proceedings of the National Academy of Sciences.

;100(11); 6688–6693.

Pinkse, Gabrielle G M, Tysma, Odette H M, Bergen, Cees A

M, Kester, Michel G D, Ossendorp F, van Veelen, Peter A ve

ark. Autoreactive CD8 T cells associated with beta cell

destruction in type 1 diabetes. Proceedings of the National

Academy of Sciences. 2005;102(51); 18425–18430.

Wedrychowicz A, Dziatkowiak H, Sztefko K. Interleukin-6

(IL-6) and IGF-IGFBP system in children and adolescents with

type 1 diabetes mellitus. Experimental and Clinical

Endocrinology & Diabetes. 2013;112(8); 435–439.

Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD,

Marcovina SM, D'Agostino, Ralph B Jr ve ark. Inflammatory

markers are increased in youth with type 1 diabetes: the

SEARCH Case-Control study. The Journal of Clinical

Endocrinology & Metabolism. 2010;95(6); 2868–2876.

Choi S, Choi K, Yoon I, Shin J, Kim J, Park W ve ark. IL-6

protects pancreatic islet beta cells from pro-inflammatory

cytokines-induced cell death and functional impairment in

vitro and in vivo. Transplant Immunology. 2004;13(1); 43–53.

Campbell IL, Hobbs MV, Dockter J, Oldstone MB, Allison J.

Islet inflammation and hyperplasia induced by the pancreatic

islet-specific overexpression of interleukin-6 in transgenic

mice. American Journal of Pathology. 1994;145(1); 157–166.

Wegner M, Araszkiewicz A, Piorunska-Stolzmann M,

Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Association

Between IL-6 Concentration and Diabetes-Related Variables in

DM1 Patients with and without Microvascular Complications.

Inflammation. 2013;36(3); 723–728.

Lee L, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S

ve ark. The role of TNF-alpha in the pathogenesis of type 1

diabetes in the nonobese diabetic mouse: analysis of dendritic

cell maturation. Proceedings of the National Academy of

Sciences. 2005;102(44); 15995–16000.

Koulmanda M, Bhasin M, Awdeh Z, Qipo A, Fan Z,

Hanidziar D ve ark. The role of TNF-α in mice with type 1- and

- diabetes. PLoS ONE. 2012;7(5); e33254.

Garber AJ. Obesity and type 2 diabetes: which patients are

at risk? Diabetes, Obesity and Metabolism. 2012;14(5); 399–

Yki-Järvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J,

Marjanen T ve ark. Effect of obesity on the response to insulin

therapy in noninsulin-dependent diabetes mellitus. The

Journal of Clinical Endocrinology & Metabolism. 1997;82(12);

–4043.

Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP,

Gomes KB. The linkage between inflammation and Type 2

diabetes mellitus. Diabetes Research and Clinical Practice.

;99(2); 85–92.

Zozulinska D, Wierusz-Wysocka B. Type 2 diabetes

mellitus as inflammatory disease. Diabetes Research and

Clinical Practice. 2006;74(2); S12.

Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M.

Quercetin ameliorates metabolic syndrome and improves the

inflammatory status in obese Zucker rats. Obesity. 2008;16(9);

–2087.

Chuang C, Martinez K, Xie G, Kennedy A, Bumrungpert A,

Overman A ve ark. Quercetin is equally or more effective than

resveratrol in attenuating tumor necrosis factor- -mediated

inflammation and insulin resistance in primary human

adipocytes. American Journal of Clinical Nutrition. 2010;92(6);

–1521.

Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does

Quercetin Improve Cardiovascular Risk factors and

Inflammatory Biomarkers in Women with Type 2 Diabetes: A

Double-blind Randomized Controlled Clinical Trial.

International Journal of Preventive Medicine. 2013;4(7); 777–

Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U,

Plachta-Danielzik S ve ark. Quercetin reduces systolic blood

pressure and plasma oxidised low-density lipoprotein

concentrations in overweight subjects with a highcardiovascular

disease risk phenotype: a double-blinded,

placebo-controlled cross-over study. British Journal of

Nutrition. 2009;102(7); 1065–1074.

Manach C, Williamson G, Morand C, Scalbert A, Remesy C.

Bioavailability and bioefficacy of polyphenols in humans. I.

Review of 97 bioavailability studies. The American Journal of

Clinical Nutrition. 2005;81(1 Suppl); 230S-242S.

. 2011; 112 (6): 318-22.

Noyan T, Balahoroğlu R, Kömüroğlu U. The Effects of Vitamin

A, E, and C Combined Insulin Treatments on the

Antioxidant Enzymes in the Diabetic Rats. Türk Klinik Biyokimya

Derg. 2004; 2(3): 113-119.